FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Swiss Dental Startup vVardis Exploring US IPO With JPMorgan, Goldman

By

Swiss dental startup vVardis is working with JPMorgan Chase (JPM) and Goldman Sachs (GS) on a potential US initial public offering that could take place this year, Bloomberg reported Tuesday, citing people familiar with the matter.

The company was valued at more than $1 billion in an April funding round and would likely seek a higher valuation in an IPO.

No final decision has been made on the offering and the company's plan could still change, according to the report.

JPMorgan Chase, Goldman Sachs, vVardis did not immediately respond to' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $297.15, Change: $+0.57, Percent Change: +0.19%

Related Articles

Wire

Thomson Reuters Building AI, Data Platform on Snowflake

Snowflake (SNOW) said Tuesday that Thomson Reuters (TRI) is building its enterprise AI and data platform using Snowflake products.The company said over 1,500 Thomson Reuters internal users like data engineers, analysts, and others use Snowflake to access governed data and generate insights for their workflows.Thomson Reuters is using Snowflake's Cortex AI to turn complex regulatory data into real-time insights and accelerate intelligent app development, as well as coding agent CoCo to allow its employees to turn legacy systems into Snowflake faster, Snowflake said.Snowflake and Thomson Reuters shares were falling 7.3% and 4.9%, respectively, in Tuesday trading.Price: $259.72, Change: $-20.44, Percent Change: -7.30%

$SNOW$TRI
Wire

Tigress Financial Adjusts MongoDB Price Target to $515 From $430, Maintains Buy Rating

MongoDB (MDB) has an average rating of overweight and mean price target of $394.34, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $389.91, Change: $-13.97, Percent Change: -3.46%

$MDB
Wire

INmune Bio Reports 'Statistically Significant Treatment Effect' in Phase 2 Alzheimer's Trial

INmune Bio (INMB) said Tuesday that a phase 2 clinical trial of its experimental drug XPro1595 demonstrated a "statistically significant treatment effect" on white matter brain biomarkers to treat patients with early onset Alzheimer's disease.The biotech firm said that while previous studies on Alzheimer's disease have focused heavily on gray matter pathology, white matter degeneration and myelin loss "are increasingly recognized as fundamental, early contributors to cognitive decline."INmune Bio said the 24-week trial evaluated patients with mild cognitive impairment and mild Alzheimer's dementia.INmune Bio shares were 1.4% higher in Tuesday trading.Price: $1.41, Change: $+0.02, Percent Change: +1.44%

$INMB